The hidden complexity of global labeling: what medical device and IVD teams need to know
Table of contents
What you’ll learn
In this blog post, you’ll explore:
- Why global labeling complexity is increasing — even for experienced RA/QA teams
- How EU MDR, EUDAMED, and accessibility mandates are reshaping content expectations
- Where multilingual labeling workflows often introduce hidden risk
- Common labeling pain points that lead to delays, rework, or compliance findings
- Practical steps medical device and IVD teams can take now to prepare with greater confidence
EU MDR, EUDAMED, accessibility, and localization challenges beneath the surface
Medical device and in vitro diagnostic (IVD) companies expanding into global markets are encountering a new layer of labeling complexity — one that goes beyond regulatory checklists alone. As regulatory expectations evolve, labeling now sits at the intersection of compliance, language, accessibility, and content integrity. Requirements such as EU MDR and EUDAMED demand greater precision and traceability. At the same time, accessibility standards and multilingual distribution introduce additional constraints that many teams underestimate until late in the process.
At its core, global labeling is no longer just about producing compliant text. It is about maintaining consistent, readable, and verifiable content across formats, languages, and review cycles — without introducing unnecessary risk or last-minute pressure.
Best practices for medical device label management and compliance
When labeling gets complex, your process needs to stay simple. This guide takes a practical look at how medical device manufacturers are managing that complexity, without slowing down or compromising accuracy.
What’s driving labeling complexity in 2026
Several converging forces are reshaping how medical device and IVD teams manage labeling and why familiar workflows are no longer sufficient.
Regulatory expectations are expanding in scope
EU MDR and EUDAMED continue to raise the bar for accuracy, transparency, and lifecycle traceability. Labeling content must remain consistent not only at submission, but throughout post-market registration.
Globalization amplifies content volume and variation
As products enter additional regions, teams must manage more languages, more artwork versions, and more review handoffs — often simultaneously.
Accessibility standards now influence labeling content
Requirements such as Section 508 of the US Rehabilitation Act and the European Accessibility Act although not aimed specifically towards Medical Devices or IVD, reinforce expectations around how information is structured, accessed, and understood by patients and healthcare professionals (HCPs).
Considerations such as reading order, live text, contrast, and digital usability increasingly shape how labeling content is evaluated once it moves beyond purely visual review.
Distributed teams increase coordination risk
CROs, CMOs, localization vendors, and internal SMEs all touch labeling content, increasing the likelihood of:
- Untracked content changes
- Formatting drift between versions
- Inconsistent interpretation of updates
- Delays caused by late-stage corrections
Individually, each pressure is manageable. Together, they create a level of complexity that requires stronger structure and visibility.
Multilingual labeling: more than translation
Global labeling initiatives often begin with translation, but translation alone does not ensure consistency.
Multilingual labeling introduces a range of subtle, high-impact challenges, including:
- Layout shifts that alter reading order
- Text expansion or contraction affecting spacing and alignment
- Differences in punctuation, word order, or emphasis
- Barcode placement inconsistencies across artwork versions
- Live text unintentionally converted to outlined fonts
These issues frequently emerge as content moves between formats and vendors, especially during file conversions such as Word to PDF or artwork handoffs. When teams rely on visual review alone, small discrepancies can persist undetected.
Accuracy in this context is quiet. It does not call attention to itself. It provides confidence that every version aligns exactly as intended.
Content integrity across formats: where errors quietly appear
As labeling content moves across formats and vendor workflows, medical device and IVD teams remain accountable for maintaining integrity end to end. A label that appears correct in one format may introduce discrepancies once it is converted, localized, or placed into artwork.
These issues rarely stem from major content changes. More often, they originate from small, quiet shifts that are difficult to detect without structured controls.
Common format-related labeling risks
Medical device and IVD teams frequently encounter integrity issues during routine file handling, including:
- Format conversions (Word/XML→InDesign/Illustrator→PDF/HTML) that alter spacing, line breaks, or character encoding
- Live text converted to outlines, making content unsearchable and harder to verify
- Font substitutions that change character spacing or reading order
- Hidden characters or tracked changes carried through from upstream documents
These risks are well understood across regulatory and accessibility frameworks, and medical device and IVD teams are expected to demonstrate control across the labeling lifecycle.
Individually, these changes may seem minor. Collectively, they can introduce content drift that compromises accuracy and traceability.
Why these errors are hard to catch
Manual review remains the default safeguard for many teams, yet format-related discrepancies are particularly challenging to detect by eye alone.
In practice, reviewers may be comparing:
- Different file types
- Different layouts
- Different visual representations of the same content
When this happens, teams are no longer validating content — they are reconciling appearances. That distinction matters.
An effective labeling process should feel calm, yet remain quietly attentive to the details others miss.
The downstream impact of format inconsistencies
Unchecked format errors can surface late in the labeling lifecycle, where correction is most costly. Common consequences include:
- Extended review cycles due to rework and clarification
- Artwork delays caused by last-minute corrections
- Regulatory findings tied to inconsistencies between submitted and released materials
- Recall risk stemming from mismatched or altered content
Maintaining content integrity across formats is more than a formatting exercise. It is a risk management discipline.
Reading order and accessibility: compliance beyond visual layout
For medical device and IVD teams, accessibility is far more than a downstream design consideration. It increasingly influences how labeling compliance is evaluated.
Standards such as Section 508 of the US Rehabilitation act and the European Accessibility Act reinforce expectations around how content is structured, navigated, and interpreted — both on screen and in print-derived formats. A label that looks correct visually may still fail accessibility review if its underlying structure does not support logical reading order or assistive technologies.
Where accessibility issues commonly arise
Accessibility-related risks often surface quietly, particularly when content moves between systems or formats. Common problem areas include:
- Incorrect reading order introduced during layout or artwork conversion
- Live text converted to outlines, preventing screen readers from accessing content
- Inconsistent heading structures that disrupt logical navigation
- Embedded images containing text without equivalent text-based alternatives
These issues are easy to overlook when teams focus primarily on visual approval. Yet accessibility compliance evaluates how content behaves, not just how it appears.
Why accessibility is a labeling concern
For regulated products, accessibility failures can create downstream consequences beyond usability. Inconsistent or inaccessible labeling may:
- Trigger regulatory findings during review
- Delay approvals due to rework
- Introduce risk for end users relying on assistive technologies
Effective accessibility practices remain calm and unobtrusive — yet stay continuously alert beneath the surface.
Managing cross-functional and vendor complexity in medical device and IVD organizations
For medical device and IVD organizations, vendor complexity does not dilute responsibility — it increases the need for clear governance.
Modern labeling workflows rarely live within a single team. Regulatory, QA, localization partners, CROs, CMOs, and artwork vendors all interact with the same content, often at different stages and in different formats.
Each handoff introduces opportunity for content drift, especially when ownership boundaries are unclear.
Where complexity compounds
Cross-functional friction often emerges when:
- Multiple vendors apply changes simultaneously
- Updates are communicated informally rather than tracked centrally
- SMEs review content without visibility into upstream or downstream changes
- Final verification relies on manual comparison alone
In these scenarios, teams may assume content consistency without having full confirmation. Small discrepancies accumulate quietly, only becoming visible late in the process.
Why visibility matters more than speed
Faster turnaround does not always mean safer outcomes. Without clear verification steps, speed can amplify risk.
Content visibility across teams allows organizations to:
- Confirm that only intended changes were made
- Reduce back-and-forth clarification cycles
- Maintain confidence across decentralized contributors
Consistency is not about control. It is about shared understanding.
How pharma and medical device technology is evolving to meet growing industry demands
As regulatory pressure, globalization, and market demands intensify, pharmaceutical and medical device companies are rapidly transforming how they manage labeling and packaging processes.
Preparing for the future: best practices that scale calmly
As regulatory, linguistic, and accessibility demands continue to converge, medical device and IVD teams benefit most from structured preparation rather than reactive fixes.
The most resilient labeling programs share a few common characteristics.
Proven practices for global labeling readiness
Teams are increasingly prioritizing:
- A single source of truth for labeling content across regions and formats
- Defined labeling taxonomy to standardize terminology and structure
- Clear ownership and handoff protocols between internal teams and vendors
- Verification checkpoints to confirm content integrity at each stage
- Traceable change management, especially during localization and artwork updates
These practices reduce ambiguity and allow teams to scale without introducing unnecessary friction.
Accuracy as a system, not a heroic effort
When processes are well-governed, accuracy becomes repeatable. Teams no longer rely on last-minute visual checks or individual vigilance alone.
Like the Sleeping Rabbit, a strong labeling system remains composed, yet never loses sight of the details that matter most.
A calm path forward for global labeling
Global labeling is becoming more complex, but complexity does not have to mean chaos.
Medical device and IVD teams that invest in clarity, structure, and content integrity will be best positioned to navigate evolving requirements with confidence. By aligning regulatory expectations, accessibility standards, and cross-functional workflows, labeling becomes a stabilizing force rather than a source of late-stage stress.
With the right foundation, accuracy is not loud or disruptive. It is quiet confidence built into every version, every language, and every release.
Teams navigating global labeling complexity benefit most from visibility and verification throughout the labeling lifecycle.
Primary regulatory sources:
https://health.ec.europa.eu/medical-devices-eudamed/overview_en
https://www.section508.gov/manage/laws-and-policies/
https://www.fda.gov/media/158522/download
https://www.fda.gov/media/102575/download
Additional edifying/inspirational sources for the writer:
https://www.orielstat.com/blog/understanding-fda-and-eu-medical-device-labeling-requirements/
